Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

909.64 +2.32 (+0.26%)
Streaming Delayed Price Updated: 2:20 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 Next >
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in 9/19 Morning Trading
Via Investor Brand Network
Regeneron Provides Update on Planned Chief Financial Officer Transition
Robert E. Landry to retire effective February 2024; Christopher Fenimore, long-standing Senior Vice President, Head of Accounting and Controller, to assume CFO role 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Announces Updates to Board of Directors
Kathryn Guarini, Ph.D., and David P. Schenkein, M.D., join Regeneron’s Board of Directors 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in 9/8 Morning Trading
Via Investor Brand Network
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in 5/19 Morning Trading
Via Investor Brand Network
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Acer Therapeutics Inc. (Nasdaq - ACER), Sovos Brands, Inc. (Nasdaq - SOVO), Computer Task Group, Incorporated (Nasdaq - CTG), Decibel Therapeutics, Inc. (Nasdaq -
From Brodsky & Smith LLC
Via GlobeNewswire
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Announces Agreement with BARDA Supporting Development of Next-Generation Antibody Therapy for COVID-19 Prevention
Program is part of U.S. Government’s ‘Project NextGen’ and provides partial funding for clinical development of a novel monoclonal antibody therapy 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Veopoz™ (pozelimab-bbfg) Receives FDA Approval as the First Treatment for Children and Adults with CHAPLE Disease
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Odronextamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
3 Strong Biotech Performers To Watch As Sector Nears Breakout
As the IBB ETF nears a potential breakout, watch for strong performers like Regeneron Pharmaceuticals, Vertex, and Exelixis to continue outperforming. 
Via MarketBeat
Topics ETFs
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ElectraMeccanica (Nasdaq - SOLO), Computer Task Group, Incorporated (Nasdaq - CTG), Decibel Therapeutics, Inc. (Nasdaq - DBTX)
From Brodsky & Smith LLC
Via GlobeNewswire
Two-year PULSAR Trial Results for Aflibercept 8 mg Demonstrate Durable Vision Gains at Extended Dosing Intervals in Wet Age-related Macular Degeneration
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Computer Task Group, Incorporated (Nasdaq - CTG), Decibel Therapeutics, Inc. (Nasdaq - DBTX)
From Brodsky & Smith LLC
Via GlobeNewswire
Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs
From Regeneron Pharmaceuticals, Inc.; Decibel Therapeutics, Inc.
Via GlobeNewswire
Regeneron Reports Second Quarter 2023 Financial and Operating Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Announces the 2023 Winners of The Regeneron Prize for Creative Innovation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Aflibercept 8 mg Two-Year Results from Pivotal PHOTON Trial in Diabetic Macular Edema Presented at ASRS
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
3 Biotech Stocks to Buy for Long-Term Gains
The biotech sector is one of the most volatile sectors, but here are three biotech stocks that offer opportunities for patient biotech stock investors. 
Via MarketBeat
Topics ETFs Economy
Exposures Interest Rates
$1 Billion Deal For Moderna To Expand Product Pipeline in China
Moderna is looking to diversify its falling U.S. product line, a $1 billion investment in China may act as the catalyst pushing the company's valuation higher 
Via MarketBeat
Topics ETFs Economy
Exposures COVID-19 Economy
Regeneron to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2023
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Two-year Results for Aflibercept 8 mg from Pivotal PHOTON Trial Demonstrate Durable Vision Gains at Extended Dosing Intervals in Diabetic Macular Edema
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
FDA Issues Complete Response Letter (CRL) for Aflibercept 8 mg Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-party Filler
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results Presented at ATS and Simultaneously Published in the New England Journal of Medicine
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023
$75,000 Top Award Goes to 17-year-old Kaitlyn Wang for breakthrough innovation to accelerate exoplanet discovery in the largest international STEM competition for teens 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.